Jonathan J. Novak

An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.8K citations · Full text

Viral Diagnostics, Worldwide Outbreak, Immunology +16

Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans

Heather Eng, Alyssa Dantonio, Eugene P. Kadar et al. · Drug Metabolism and Disposition · 2022 · 111 citations · Full text

Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity

Brahim Achour, Alyssa Dantonio, Mark Niosi et al. · Drug Metabolism and Disposition · 2017 · 40 citations · Full text

PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease

Ariamala Gopalsamy, Ann Aulabaugh, Amey Barakat et al. · Journal of Medicinal Chemistry · 2020 · 40 citations · Full text

Mechanistic insights on clearance and inhibition discordance between liver microsomes and hepatocytes when clearance in liver microsomes is higher than in hepatocytes

Christopher Keefer, George Chang, Anthony Carlo et al. · European Journal of Pharmaceutical Sciences · 2020 · 36 citations

Chromatin, Hepatology, Biochemistry +15